elliptinium has been researched along with Bone Marrow Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abele, R; Brugarolas, A; Cavalli, F; Clarysse, A; de Jager, R; Hansen, HH; Renard, G; Rozencweig, M; Siegenthaler, P | 1 |
| Crespeigne, N; Cumps, E; Dodion, P; Kenis, Y; Kisner, D; Nicaise, C; Piccart, M; Rozencweig, M | 1 |
2 other study(ies) available for elliptinium and Bone Marrow Diseases
| Article | Year |
|---|---|
Phase II study of 9-hydroxy-2N-methylellipticinium acetate.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; Bone Marrow Diseases; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Evaluation; Ellipticines; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms | 1984 |
Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; Bone Marrow Diseases; Drug Administration Schedule; Drug Evaluation; Ellipticines; Female; Humans; Male; Middle Aged; Neoplasms | 1982 |